

## Note

### Synthesis of methyl-5-[2-arylamino-4-(3-oxo-1,4-benzoxazin-6-yl)thiazole acetates and 7*H*-[3-aryl-6-(3-oxo-1,4-benzoxazin-6-yl)-*s*-triazolo[3,4-*b*][1,3,4]thiadiazin-7-yl]acetates as possible COX-2-inhibitors

G Jagath Reddy\* & K Srinivasa Rao

R & D Laboratories, Dr. Jagath Reddy's Heterocyclics, 81, S.V.Co-op Industrial Estate, Balanagar, Hyderabad 500 037, India

E-mail: jagathreddy@usa.net

K N Jayaveera & S Sailaja

Oil Technological Research Institute, Jawaharlal Nehru Technological University, Anantpur 515 001

and

P Reddanna & D Bharat Reddy

School of Life Sciences, Universities of Hyderabad, Hyderabad 500 046, India

Received 6 June 2005; accepted (revised) 17 April 2006

A series of methyl 5-[2-arylamino-4-(3-oxo-[1,4]benzoxazin-6-yl)thiazoleacetates **5a-h** and 7*H*-[3-aryl-6-(3-oxo-[1,4]-benzoxazin-6-yl)-*s*-triazolo[3,4-*b*][1,3,4]thiadiazin-7-yl]acetates **6a-e** have been synthesized and tested for their COX-2 inhibitor activity.

**Keywords:** Benzoxazin, *v*-bromobenzoxazinyl butanoate, thiazolyl-benzoxazinyl acetates, triazolothiadiazinyl benzoxazinyl acetate, COX-2 inhibitors.

**IPC Code:** Int.Cl.<sup>8</sup> C07D


Thiazole ring system plays an important role in a number of heterocycles with wide spectrum of biological activity such as antibacterial, antifungal and antiviral<sup>1</sup>. Thiazole containing natural products are known for their antibiotic and antifungal activities<sup>2</sup>. A number of marine products with thiazole ring exhibit antineoplastic and cytotoxic activities<sup>3</sup>. Thiazole acetic acids like Fentiazac and Fenclozic acid are known for their anti-inflammatory activities<sup>4</sup>. Several *s*-triazolothiadiazines have found potential application as antibacterial, antifungal and anti-inflammatory agents<sup>5</sup>. Furthermore, 3-oxo-1,4-benzoxazines substituted with a heterocycle in the aromatic ring have shown excellent pharmacological profiles and are found useful in the treatment of congestive heartfailure<sup>6</sup>, breast cancer<sup>7</sup>, CNS diseases<sup>8</sup> and as inhibitors of transforming growth factors<sup>9</sup>. In

view of this and in continuation of our work on benzoxazines<sup>10</sup>, we report herein the synthesis of benzoxazinylthiazolyl acetates and triazolo-thiadiazinylacetates as possible COX-2 inhibitors.

Fridel-Crafts acylation of 3-oxo-3,4-dihydro-2*H*-[1,4]-benzoxazine **1** with succinic anhydride and aluminium chloride according to the reported procedure<sup>6</sup> gave the oxobutyric acid **2**. Esterification of **2** followed by bromination in carbon tetrachloride gave the  $\alpha$ -bromoketoester **4** in excellent yields. <sup>1</sup>H NMR spectra of **4** exhibited three sets of double doublets at  $\delta$  3.06, 3.42 and 5.46 for CH<sub>2</sub>-CH-Br protons and two singlets at  $\delta$  3.67 and 4.64 for methyl ester and -OCH<sub>2</sub> protons of benzoxazine ring. The lactam NH of benzoxazine ring appeared as a broad singlet at  $\delta$  10.73. Reactions of **4** with various substituted thioureas and 3-mercaptop-4-amino-*s*-triazoles in refluxing methanol gave the corresponding benzoxazinylthiazolylacetates **5** and benzoxazinyltriazolo-thiadiazinyl acetates **6** respectively in good yields (**Scheme I**). The formation of thiazolyl **5** and triazolothiadiazinyl benzoxazines **6** is evident from the disappearance of three sets of double doublets for -CO-CHBr-CH<sub>2</sub> system present in **4** and appearance of three singlets around  $\delta$  3.67, 3.78 and 4.60 for CH<sub>2</sub>CO<sub>2</sub>CH<sub>3</sub>, CO<sub>2</sub>CH<sub>3</sub> and -OCH<sub>2</sub> of benzoxazine ring protons in **5** whereas triazolothiadiazinylbenzoxazines **6** were characterized by the presence of signals around  $\delta$  2.8 (m, CH<sub>2</sub>CO<sub>2</sub>CH<sub>3</sub>), 3.6 (s, CO<sub>2</sub>CH<sub>3</sub>), 4.8 (dd, -SCH) apart from benzoxazine ring protons around 4.6 (s, -OCH<sub>2</sub>) and 10.2 (bs, NH). All the compounds reported in **Table I** were based on IR, <sup>1</sup>H NMR, mass spectra and correct elemental analysis.

### COX-2 Inhibitor activity

All the compounds reported in **Table I** were tested for cyclooxygenase-2 inhibitory activity. The method of Copeland *et al.*<sup>11</sup> was followed to determine the IC<sub>50</sub> values. The enzyme activity was measured using chromogenic assay based on oxidation of N,N,N',N'-tetramethylparaphenylenediamine (TMPD) during the reduction of prostaglandin G<sub>2</sub> to prostaglandin H<sub>2</sub> by COX-1 and COX-2 enzymes. COX-1 enzyme is from ram seminal vesicles (microsomal fraction) and COX-2 is recombinant human enzyme purified from



Scheme I

Table I — Characterization data of compounds **5a-h** and **6a-f**

Compd*	R <sub>1</sub>	m.p. °C	Yield (%)	Mol. formula	Found (Calcd) %			<sup>1</sup> H NMR (δ, ppm) CDCl <sub>3</sub> +DMSO-d <sub>6</sub>	MS m/z [M <sup>+</sup> ]
					C	H	N		
<b>5a</b>	H	193	69	C <sub>14</sub> H <sub>13</sub> N <sub>3</sub> O <sub>4</sub> S	52.78 (52.66)	4.26 4.07	13.41 13.16	3.69(s, 2H), 3.78(s, 3H), 4.56(s, 2H), 7.06(m, 3H), 8.65(bs, 2H), 10.67(bs, 1H)	319
<b>5b</b>	C <sub>6</sub> H <sub>5</sub>	179	74	C <sub>20</sub> H <sub>17</sub> N <sub>3</sub> O <sub>4</sub> S	61.03 (60.75)	4.32 4.03	10.86 10.63	3.64(s, 2H), 3.76(s, 3H), 4.62(s, 2H), 7.14-7.63(m, 8H), 10.18(bs, 1H), 10.76(bs, 1H)	395
<b>5c</b>	4-CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	157	72	C <sub>21</sub> H <sub>19</sub> N <sub>3</sub> O <sub>4</sub> S	61.83 (61.61)	4.79 4.64	10.43 10.26	2.32(s, 3H), 3.67(s, 2H), 3.72(s, 3H), 4.57(s, 2H), 6.78-7.17(m, 7H), 9.37(bs, 1H), 9.78(bs, 1H)	409
<b>5d</b>	4-CH <sub>3</sub> OC <sub>6</sub> H <sub>4</sub>	173	71	C <sub>21</sub> H <sub>19</sub> N <sub>3</sub> O <sub>5</sub> S	59.26 (59.01)	4.62 4.44	10.21 9.83	3.65(s, 2H), 3.71(s, 3H), 3.80(s, 3H), 4.59(s, 2H), 6.81-7.19(m, 7H), 9.41(bs, 1H), 9.81(bs, 1H)	425
<b>5e</b>	4-ClC <sub>6</sub> H <sub>4</sub>	183	76	C <sub>20</sub> H <sub>16</sub> ClN <sub>3</sub> O <sub>4</sub> S	56.13 (55.87)	4.06 3.72	9.53 9.77	3.65(s, 2H), 3.79(s, 3H), 4.61(s, 2H), 7.16(m, 5H), 7.63(m, 2H), 10.14(bs, 1H), 10.78(bs, 1H)	429
<b>5f</b>	4-FC <sub>6</sub> H <sub>4</sub>	181	77	C <sub>20</sub> H <sub>16</sub> FN <sub>3</sub> O <sub>4</sub> S	58.42 (58.11)	4.21 3.87	10.43 10.16	3.66(s, 3H), 3.82(s, 2H), 4.60(s, 2H), 7.12(m, 5H), 7.65(m, 2H), 10.16(bs, 1H), 10.79(bs, 1H)	413
<b>5g</b>	2,4-diFC <sub>6</sub> H <sub>3</sub>	237	78	C <sub>20</sub> H <sub>15</sub> F <sub>2</sub> N <sub>3</sub> O <sub>4</sub> S	55.82 (55.68)	3.64 3.48	10.12 9.74	3.67(s, 2H), 3.76(s, 3H), 4.62(s, 2H), 7.15-7.62(m, 6H), 10.17(bs, 1H), 10.78(bs, 1H)	431
<b>5h</b>	3-Cl,4-FC <sub>6</sub> H <sub>3</sub>	197	76	C <sub>20</sub> H <sub>15</sub> ClFN <sub>3</sub> O <sub>4</sub> S	53.89 (53.63)	3.62 3.35	9.74 9.38	3.66(s, 2H), 3.78(s, 3H), 4.61(s, 2H), 7.14-7.63(m, 6H), 10.16(bs, 1H), 10.76(bs, 1H)	447
<b>6a</b>	C <sub>6</sub> H <sub>5</sub>	175	72	C <sub>21</sub> H <sub>17</sub> N <sub>5</sub> O <sub>4</sub> S	58.21 (57.93)	4.19 3.90	16.26 16.09	2.67(m, 2H), 3.62(s, 3H), 4.63(s, 2H), 4.84(dd, 1H), 7.43-7.68(m, 8H), 10.54(bs, 1H)	434
<b>6b</b>	4-CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	183	74	C <sub>22</sub> H <sub>19</sub> N <sub>5</sub> O <sub>4</sub> S	58.92 (58.79)	4.56 4.23	15.72 15.59	2.34(s, 3H), 2.66(m, 2H), 3.64(s, 3H), 4.62(s, 2H), 4.82(dd, 1H), 7.44- 7.71(m, 7H), 10.67(bs, 1H)	448
<b>6c</b>	4-ClC <sub>6</sub> H <sub>4</sub>	199	76	C <sub>21</sub> H <sub>16</sub> ClN <sub>5</sub> O <sub>4</sub> S	53.78 (53.67)	3.46 3.40	15.21 14.90	2.68(m, 2H), 3.68(s, 3H), 4.60(s, 2H), 4.81(dd, 1H), 7.38-7.67(m, 7H), 10.68(bs, 1H)	468

Contd

**Table I** — Characterization data of compounds **5a-h** & **6a-f** — *Contd*

Compd*	R <sub>1</sub>	m.p. °C	Yield (%)	Mol. formula	Found (Calcd) %			<sup>1</sup> H NMR (δ, ppm) CDCl <sub>3</sub> +DMSO-d <sub>6</sub>	MS m/z [M <sup>+</sup> ]
					C	H	N		
<b>6d</b>	4-FC <sub>6</sub> H <sub>4</sub>	195	77	C <sub>21</sub> H <sub>16</sub> FN <sub>5</sub> O <sub>4</sub> S	55.84 (55.62)	3.76 3.53	15.78 15.45	2.66(m, 2H), 3.67(s, 3H), 4.54(s, 2H), 4.84(dd, 1H), 7.41-7.69(m, 7H), 10.63(bs, 1H)	452
<b>6e</b>	2,4-diClC <sub>6</sub> H <sub>3</sub>	233	75	C <sub>21</sub> H <sub>15</sub> Cl <sub>2</sub> N <sub>5</sub> O <sub>4</sub> S	50.26 (50.00)	3.26 2.97	13.61 13.88	2.67(m, 2H), 3.66(s, 3H), 4.61(s, 2H), 4.84(dd, 1H), 7.45-7.67(m, 6H), 10.69(bs, 1H)	503
<b>6f</b>	4-C <sub>5</sub> H <sub>5</sub> N	247	68	C <sub>20</sub> H <sub>16</sub> N <sub>6</sub> O <sub>4</sub> S	55.37 (55.09)	3.93 3.66	19.41 19.26	2.61(m, 2H), 3.65(s, 3H), 4.64(s, 2H), 4.83(dd, 1H), 7.42-7.91(m, 7H), 10.71(bs, 1H)	435

SF<sub>9</sub> cells (microsomal fraction) were used in the assay.

The compounds were dissolved in DMSO and stock solution was diluted to required assay concentration. The assay mixture consists of tris buffer (pH 8.0), EDTA solution and hematin as cofactor, the enzyme and the drug of assay concentration in DMSO. The assay mixture was pre-incubated at 250°C and then TMPD in ethanol was added. The enzyme activity was measured by estimating the initial velocity during the first 25 seconds by measuring the absorbance at 603 nm. IC<sub>50</sub> values are calculated from four parameter least squares nonlinear regression analysis of the log dose versus percentage inhibition plot. However, none of the compounds reported herein exhibited significant inhibitions up to 100 μM except **5a** which exhibited a low order of inhibitions (31%) when compared to Celecoxib with 98% inhibition at 5 μM.

## Experimental Section

Melting points were determined in open capillaries and are uncorrected. The purity of all the compounds was routinely checked by TLC on silica gel coated plates. IR spectra were recorded on KBr pellets on a Perkin-Elmer system 2000 FT IR spectrometer. <sup>1</sup>H NMR spectra on a Varian 200 MHz instrument with TMS as internal standard and chemical shifts expressed in δ ppm and mass spectra on Hewlett Packard mass spectrometer operating at 70 eV.

**Methyl-[v-bromo-β-oxo-(2H - 3-oxo-1,4-benzoxazin-6-yl)]butanoate 4.** To a mixture of methyl-β-oxo-(2H-3-oxo-1,4-benzoxazin-6-yl)butanoate (**3**, 2.61 g, 0.01 mole) in dichloromethane (200 mL) was added bromine (1.8 moles) in dichloromethane (15 mL) at room temperature. The mixture was refluxed for 3-4 hr. At the end of the reaction as monitored by TLC it was poured onto ice water. The organic layer was separated, washed with water (2 × 50 mL), dried

(Na<sub>2</sub>SO<sub>4</sub>) and solvent removed to get a solid. It was recrystallized from dichloromethane to give pure **4** as light yellow crystalline solid. M.p. 189°C, yield 85%. IR (KBr): 1720, 1690 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>+DMSO-d<sub>6</sub>): δ 3.06 (dd, 1H), 3.42 (dd, 1H), 3.67 s, 3H), 4.64 (s, 2H), 5.46 (dd, 1H), 7.01 (d, 1H), 7.32 (m, 2H), 10.73 (bs, 1H); MS m/z [M<sup>+</sup>]: 341 (Found: C, 45.83; H, 3.76; N, 4.21, C<sub>13</sub>H<sub>12</sub>BrNO<sub>5</sub> requires C, 45.62; H, 3.51; N, 4.09%).

**General procedure for the preparation of methyl- 5-[2 - arylamino-4-(3 - oxo-1,4-benzoxazin-6-yl)thiazole acetates 5.** A mixture of **4** (0.01 mole) and arylamino thiourea in methanol (50 mL) was refluxed for 4-5 hr. At the end of the reaction as monitored by TLC, solvent was removed *in vacuo*, the residue was treated with NaHCO<sub>3</sub> solution to neutral pH. The separated solid was filtered and recrystallized with methanol to give pure **5** as crystalline solids.

Compounds **5a-h** were prepared similarly and their characterization data are listed in **Table I**.

**General procedure for the preparation of methyl-[7H-3-aryl-6-(3-oxo-1,4-benzoxazin-6-yl)-s-triazolo[3,4-b][1,3,4]thiadiazin-7-yl]acetates 6.** A mixture of **4** (0.01 mole) and 3-mercaptop-4-amino-5-aryl-s-triazole (0.01 mole) in methanol (50 mL) was refluxed for 4-5 hr. At the end of the reaction as monitored by TLC, solvent was removed *in vacuo*, the residue was treated with NaHCO<sub>3</sub> solution to neutral pH. The separated solid was filtered and recrystallized from methanol to give pure **6** as crystalline solids.

Compounds **6a-f** were prepared similarly and their characterization data are listed in **Table I**.

## References

- 1 Dondoni A & Merino P in *Comprehensive Heterocyclic Chemistry II*, 3, **1996**, 467.
- 2 Shao J & Panek J S, *Organic letters*, 6(18), **2004**, 3083.

- 3 Agullar E & Meylers A I, *Tetrahedron lett*, **1994**, 2473.
- 4 *Merck Index*, 13<sup>th</sup> edition, 3996, 4031, p, no. 702, 709, **2001**.
- 5 a) Bhalla M, Hitkari A, Gujrati V R, Bhalla T N & Shankar K, *Eur J Med Chem*, **29**, **1994**, 713.  
b) Mazzone G, Barina F, Pignattallo R, Panico A H, Caruso A, Leone M G, Amico-Roxas M & Blendino G, *Farmaco*, **44** (10) **1989**, 933; *Chem Abstr*, **112**, 191380n, **1990**.  
c) Lec A R T, US 5, 498, 720, **1996**; *Chem Abstr*; **125**: 10824K, **1996**.
- 6 a) Combs D W, Rampulla M S, Bell S C, Klaubert D H, Tobia A J, Falotica R, Heartlein B, Lakas-Weiss C & Moor J B, *J Med Chem*, **33**, **1990**, 380.  
b) Reddy Sastry C V, Srinivasa Rao K, Krishnan V S H, Rastogi K, Jain M L, Varma R K, Tripathi R M, Singh P P, Seshagiri Rao C & Kaushal R, *Indian J Chem*, **28B**, **1989**, 882.
- 7 Blerer D, Machure A, Fu W, Achibe F, Ladouceur G H, Burke M J, Bichary, Hart B, Dumas J, Sibley R, Scott W J, Johnson J, Asgani D, P C T, Int W003 27, 085, **2003**; *Chem Abstr*, **138**, 287663v, **2003**.
- 8 Maig H, Sui H & Zhao S A, US 92, 512, **2004**; *Chem Abstr* **140**, 406825, **2004**.
- 9 Gellibert F J & Jayne A H, P C T, Int W003, 97, 639, **2004**; *Chem Abstr*, **140**, 5057t, **2004**.
- 10 a) Jagath Reddy G, Sailaja S, Srinivasa Rao K, Reddanna P & Bharat Reddy P, *Indian J Chem*, **44B**, **2005**, 204.  
b) Reddy P S N, Reddy Pragati, Jagath Reddy G & Srinivasa Rao K, *Heterocyclic Commun*, **9**, **2003**, 503.
- 11 Copeland R A, Willianes J M, Giamars J, Namberg S, Corington M, Pinto D, Pick S & Trzaskos J M, *Nat Acad Sci*, USA, **91**, **1994**, 11202.